Related references
Note: Only part of the references are listed.Identification of factors influencing the pharmacokinetics of voriconazole and the optimization of dosage regimens based on Monte Carlo simulation in patients with invasive fungal infections
Taotao Wang et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2014)
Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology
H. Ruth Ashbee et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2014)
Population-Based Analysis of Invasive Fungal Infections, France, 2001-2010
Dounia Bitar et al.
EMERGING INFECTIOUS DISEASES (2014)
The Effect of Therapeutic Drug Monitoring on Safety and Efficacy of Voriconazole in Invasive Fungal Infections: A Randomized Controlled Trial
Wan Beom Park et al.
CLINICAL INFECTIOUS DISEASES (2012)
Challenging Recommended Oral and Intravenous Voriconazole Doses for Improved Efficacy and Safety: Population Pharmacokinetics-Based Analysis of Adult Patients With Invasive Fungal Infections
Andres Pascual et al.
CLINICAL INFECTIOUS DISEASES (2012)
Steady-State Plasma Pharmacokinetics of Oral Voriconazole in Obese Adults
Manjunath P. Pai et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Observational Study of the Clinical Efficacy of Voriconazole and Its Relationship to Plasma Concentrations in Patients
Peter F. Troke et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Fusarium verticillioides fungemia in a liver transplantation patient: successful treatment with voriconazole
Stefania Cocchi et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2011)
Voriconazole Pharmacokinetics in Liver Transplant Recipients
H. J. Johnson et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Correlation between voriconazole trough plasma concentration and hepatotoxicity in patients with different CYP2C19 genotypes
Kazuaki Matsumoto et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2009)
Monitoring trough concentration of voriconazole is important to ensure successful antifungal therapy and to avoid hepatic damage in patients with hematological disorders
Koki Ueda et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2009)
CYP2C19 Genotype Is a Major Factor Contributing to the Highly Variable Pharmacokinetics of Voriconazole
Johanna Weiss et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Antifungal drugs: predicting clinical efficacy with pharmacodynamics
Michael D Nailor et al.
Expert Review of Clinical Pharmacology (2009)
Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes
Andres Pascual et al.
CLINICAL INFECTIOUS DISEASES (2008)
Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses study group and European Organization for Research and Treatment of Cancer consensus criteria
Brahm H. Segal et al.
CLINICAL INFECTIOUS DISEASES (2008)
Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group
Ben De Pauw et al.
CLINICAL INFECTIOUS DISEASES (2008)
Antifungal agents - clinical pharmacokinetics and drug interactions
Hans-Peter Lipp
MYCOSES (2008)
Contribution of the (1→3)-β-D-glucan assay for diagnosis of invasive fungal infections
Florence Persat et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2008)
Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients
Steve Trifilio et al.
CANCER (2007)
Variability of voriconazole plasma levels measured by new high-performance liquid chromatography and bioassay methods
Andres Pascual et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Voriconazole - A review of its use in the management of invasive fungal infections
Lesley J. Scott et al.
DRUGS (2007)
Invasive fungal pathogens: Current epidemiological trends
Michael A. Pfaller et al.
CLINICAL INFECTIOUS DISEASES (2006)
Clinical pharmacokinetics of voriconazole
Dominique Levque et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2006)
Correlation of MIC with outcome for Candida species tested against voriconazole:: Analysis and proposal for interpretive breakpoints
MA Pfaller et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2006)
Pharmacokinetic/pharmacodynamic profile of voriconazole
Ursula Theuretzbacher et al.
CLINICAL PHARMACOKINETICS (2006)
Improved outcome in central nervous system aspergillosis, using voriconazole treatment
S Schwartz et al.
BLOOD (2005)
Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: Variables that affect performance
KA Marr et al.
JOURNAL OF INFECTIOUS DISEASES (2004)
Pharmacokinetics of voriconazole and cytochrome P450 2C19 genetic status
Y Ikeda et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2004)
In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model
D Andes et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2003)
Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole
R Hyland et al.
DRUG METABOLISM AND DISPOSITION (2003)
Share Paper
